SCHEMBL2833280

SCHEMBL2833280

CC(C)(C)OC(=O)NC(c1ccc(Cl)cc1F)C(O)c1ccc(I)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 6/20 0.42
CYP3A4 P08684 4/20 0.40
CYP3A5 P20815 4/20 0.40
KDM4D Q6B0I6 1/20 0.39
S1PR1 P21453 2/20 0.36
TRPA1 O75762 2/20 0.36
APP P05067 1/20 0.36
AAK1 Q2M2I8 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
CTSL P07711 1/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15962609 0.86 S1PR3 (0.45) S1PR3CYP3A4CYP3A5KDM4DTRPA1
SCHEMBL2837541 0.83 S1PR3 (0.38) S1PR3S1PR1TRPA1APPAAK1
SCHEMBL2833955 0.80 MDM2 (0.50) S1PR3CYP3A4CYP3A5KDM4DS1PR1
SCHEMBL2834769 0.79 ALDH1A1 (0.41) S1PR3TRPA1AAK1ALDH1A1TP53
SCHEMBL2834220 0.79 S1PR3 (0.42) S1PR3CYP3A4AAK1ALDH1A1SMN1; SMN2
SCHEMBL24645224 0.78 TRPA1 (0.45) S1PR3TRPA1KDM4EALDH1A1GAA
SCHEMBL15989522 0.78 TRPA1 (0.45) S1PR3TRPA1KDM4EALDH1A1GAA
SCHEMBL15989527 0.78 TRPA1 (0.45) S1PR3TRPA1KDM4EALDH1A1GAA
SCHEMBL2837593 0.77 PDE2A (0.40) AAK1
SCHEMBL2833402 0.77 MEN1 (0.36) S1PR3S1PR1TRPA1AAK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CYP3A4 1043/4885CYP3A5 931/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885CYP3A4 1043/4885CYP3A5 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.